Why the study?
Do inhibitors of the renin-angiotensin system reduce new-onset diabetes in patients with insulin resistance?
Do inhibitors of the renin-angiotensin system reduce new-onset diabetes in patients with insulin resistance?
Inhibitors of the renin-angiotensin system are associated with a significant reduction in new-onset diabetes in patients with insulin resistance, supported by cross-talk between angiotensin and insulin signaling pathways.
Answers are grounded in this paper and cite their sources.
Supports potential diabetes prevention with RAS inhibitors in insulin resistance; leaves open need for randomized confirmation.
Several large-scale clinical studies have consistently demonstrated that use of inhibitors of renin-angiotensin system such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers was associated with significant reduction of new-onset diabetes in patients with insulin resistance such as primary hypertension. Such observations stimulated major investigations into the interaction of angiotensin and insulin signaling systems, which in turn led to the discovery of a cross talk at several steps between the 2 pathways. Evidence from these clinical trials and from the experimental models of insulin resistance including our findings in ZSF rat and other animal models will be discussed in this review.
No takes yet. Share an insight, caveat, or question.
Sharma Prabhakar (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: